Gina Columbus
Articles
FDA Approves Belantamab Mafodotin-blmf to Treat R/R Multiple Myeloma
August 06, 2020
Article
The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma
July 24, 2020
Article
The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell lymphoma (MCL).
FDA Panel OKs Belantamab Mafodotin for Relapsed/Refractory Myeloma
July 15, 2020
Article
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 0 in favor of approving belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have previously received at least 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and a CD38-directed antibody.
Global COVID-19 Observatory and Resource Center for Childhood Cancer Helps Providers During the Pandemic
June 30, 2020
Article
Following the arrival of the coronavirus disease 2019 pandemic, St. Jude Children's Research Hospital launched the first Global COVID-19 Observatory and Resource Center for Childhood Cancer.
Neoadjuvant Melanoma Combo Improves RFS in Macroscopic Melanoma
June 25, 2020
Article
Nivolumab plus ipilimumab showed an improvement in relapse-free survival for this patient population.
Immunotherapy/Chemotherapy Regimen Improves Lung Cancer Outcomes, Regardless of Biomarker Status
June 23, 2020
Article
The combination of atezolizumab (Tecentriq) plus carboplatin/etoposide continued to demonstrate an improvement in overall survival (OS) versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), regardless of PD-L1 and blood tumor mutational burden (bTMB) status.
Expert Offers Tips on Telemedicine
June 10, 2020
Article
Telemedicine will remain a mainstay even after the COVID-19 pandemic, says Andrew M. Evens, DO, MSc.
Infigratinib Is Active in Metastatic Urothelial Cancer
June 02, 2020
Article
Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered, according to results of a retrospective analysis presented at the 2020 ASCO Virtual Scientific Program.
Trastuzumab Deruxtecan Granted Orphan Drugs Status for Gastric Cancer
May 22, 2020
Article
The FDA has granted an orphan drug designation to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with gastric cancer, including gastroesophageal junction (GEJ) cancer.
Blood Test Shows Promise for Early Cancer Detection
April 29, 2020
Article
A minimally invasive blood test has been found to be feasible to safely detect several types of cancers in patients without a history of malignancies, enabling treatment with curative intent in a subset of individuals, according to real-world results of an interim analysis of the DETECT-A study presented at the 2020 AACR Virtual Annual Meeting.